Aliskiren

被引:3
|
作者
Anderson, David Leif [1 ]
机构
[1] Dept Med Informat, Barcelona 08025, Spain
关键词
D O I
10.1358/dot.2007.43.12.977448
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aliskiren (CGP-60536 or SPP1100) is the first oral direct renin inhibitor and the first new class of antihypertensive agents to be introduced in more than a decade. Aliskiren taken once a day, alone or in combination with other anti hypertensive agents, has been shown to be effective in reducing blood pressure and is generally well tolerated. Based on an extensive clinical trials program, aliskiren was approved for the treatment of hypertension in March 2007 (as Tekturna((R)); Novartis Pharmaceuticals, East Hanover, NJ, USA) by the U.S. Food and Drug Administration and in August 2007 (as Rasilez((R)), Enviage((R)), Sprimeo((R)), Tekturna((R)) and Riprazo((R)), all from Novartis) for the treatment of essential hypertension by the European Commission. Although the indication for aliskiren is treatment of essential hypertension, benefits similar to those demonstrated with certain angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) are anticipated for aliskiren. Some of the 44 trials with aliskiren are listed in Table II. Inhibition of renin, which is the first and rate-limiting step in the renin-angiotensin pathway has theoretical advantages over either ACE inhibitors or ARBs. (c) 2007 Prous Science. All rights reserved.
引用
收藏
页码:849 / 855
页数:7
相关论文
共 50 条
  • [31] Effectiveness and Safety of Aliskiren and Aliskiren Hydrochlorothiazide (HCT) in a Multiethnic, Real-World Setting
    Srinivasa Rao Maddury
    Abhay Pande
    K. M. H. S. Sirajul Haque
    Akram Echtay
    Loewe Go
    Tashbeeb Gulzar
    Mahomed Kadwa
    Sashka Hristoskova
    Advances in Therapy, 2013, 30 : 176 - 189
  • [32] Clinical pharmacokinetics and pharmacodynamics of Aliskiren
    Vaidyanathan, Sujata
    Jarugula, Venkateswar
    Dieterich, Hans Armin
    Howard, Dan
    Dole, William P.
    CLINICAL PHARMACOKINETICS, 2008, 47 (08) : 515 - 531
  • [33] Aliskiren (Tekturna) for the treatment of hypertension
    Bernknopf, Allison
    AMERICAN FAMILY PHYSICIAN, 2007, 76 (08) : 1203 - 1204
  • [34] Aliskiren Induced Remarkable Hypertriglyceridemia
    Azushima, Kengo
    Tamura, Kouichi
    Wakui, Hiromichi
    Maeda, Akinobu
    Kanaoka, Tomohiko
    Ohsawa, Masato
    Haku, Sona
    Uneda, Kazushi
    Toya, Yoshiyuki
    Umemura, Satoshi
    INTERNAL MEDICINE, 2012, 51 (24) : 3387 - 3389
  • [35] Good news from Aliskiren?
    Verdecchia, Paolo
    Angeli, Fabio
    Reboldi, Gianpaolo
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 999 - 1002
  • [36] Aliskiren, ALTITUDE, and the implications for ATMOSPHERE
    McMurray, John J. V.
    Abraham, William T.
    Dickstein, Kenneth
    Kober, Lars
    Massie, Barry M.
    Krum, Henry
    EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (04) : 341 - 343
  • [37] Hypotension after ingestion of Aliskiren
    Spiller, Henry A.
    CLINICAL TOXICOLOGY, 2008, 46 (09) : 916 - 917
  • [38] Aliskiren for the Treatment of Hypertension: An Update
    Lam, S.
    Saxena, S.
    Macina, L. O.
    Lester, P. E.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 727 - 734
  • [40] Formal Total Synthesis of Aliskiren
    Peters, Byron K.
    Liu, Jianguo
    Margarita, Cristiana
    Andersson, Pher G.
    CHEMISTRY-A EUROPEAN JOURNAL, 2015, 21 (19) : 7292 - 7296